Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Low Grade Glioma — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
Neuroepithelial Neoplasm
Glioma
Low Grade Glioma

Subtype

Low Grade Glioma

CI-CAN-00003062LGGExplore in graph →

Non-malignant115 active trials62 evidence items

NCIt: C132067
OncoTree: LGGNOS
DOID: 0080829
Other: 1 more code

Overview
Statistics
Survival
Genomics2
Variants & evidence62
Drugs13
Trials324
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (39)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–25 of 39 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
· N Engl J Med · 2023 · PMID 37272516 · validated civic_curation pubmed
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
· Nat Med · 2024 · PMID 37978284 · validated civic_curation pubmed
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.
· J Clin Oncol · 2023 · PMID 36375115 · validated civic_curation pubmed
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
· Acta Neuropathol · 2016 · PMID 27157931 · validated civic_curation pubmed
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
· Nat Genet · 2013 · PMID 23817572 · validated cbioportal_study pubmed
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
· J Clin Oncol · 2009 · PMID 19901104 · validated civic_curation pubmed
Pediatric low-grade gliomas can be molecularly stratified for risk.
· Acta Neuropathol · 2018 · PMID 29948154 · validated civic_curation pubmed

Showing 1–25 of 39 publications

← Previous
1
2
Next →

BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma.

· Clin Cancer Res · 2011 · PMID 21610142 · validated civic_curation pubmed

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.

· Nat Genet · 2013 · PMID 23583981 · validated civic_curation pubmed

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.

· Cancer Res · 2008 · PMID 18974108 · validated civic_curation pubmed

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.

· Cancer Cell · 2015 · PMID 25965575 · validated civic_curation pubmed

MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism.

· Nat Genet · 2016 · PMID 26829751 · validated civic_curation pubmed

A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration.

· Acta Neuropathol · 2019 · PMID 31595312 · validated civic_curation pubmed

Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course.

· Acta Neuropathol · 2020 · PMID 31563982 · validated civic_curation pubmed

Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.

· Proc Natl Acad Sci U S A · 2013 · PMID 23633565 · validated civic_curation pubmed

Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features.

· Brain Pathol · 2019 · PMID 30246434 · validated civic_curation pubmed

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

· Neuro Oncol · 2022 · PMID 35395680 · validated civic_curation pubmed

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

· Lancet Oncol · 2019 · PMID 31151904 · validated civic_curation pubmed

C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma.

· Nature · 2014 · PMID 24553141 · validated civic_curation pubmed

A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial ZFTA-fused ependymoma.

· Neurooncol Adv · 2023 · PMID 37287693 · validated civic_curation pubmed

Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial.

· Neuro Oncol · 2019 · PMID 30976811 · validated civic_curation pubmed

Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation of the NF-κB signaling pathway.

· Acta Neuropathol · 2014 · PMID 24562983 · validated civic_curation pubmed

Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.

· Acta Neuropathol · 2016 · PMID 26810070 · validated civic_curation pubmed

Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002).

· Oncotarget · 2020 · PMID 32523649 · validated civic_curation pubmed

Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.

· Cancer · 2006 · PMID 16541434 · validated civic_curation pubmed